

Tristel plc
(“Tristel” or “the Company”)

Issue of Equity/Director dealing

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, today announces that yesterday 475,000 ordinary shares of 1 penny each in the capital of the Company (“Ordinary Shares”) were issued and allotted pursuant to the exercise of share options under a variety of different schemes.

The above figure includes 250,000 ordinary shares which were allotted to Paul Swinney, CEO, under the Senior Management Share Option Scheme and were due to expire later this year. These options were exercised at a price of 59p. Mr Swinney yesterday sold the 250,000 shares allotted at a price of 109p per Ordinary Share. Accordingly Mr Swinney’s shareholding remains unchanged at 915,000 ordinary shares, representing 2.18% of the issued share capital. In addition he now holds 1,399,179 options under the Senior Management Share Option Scheme, of which 485,000 are exercisable.

Application has been made for the 475,000 new Ordinary Shares to be admitted to trading on AIM (“Admission”) and dealings are expected to commence on 21 October 2015. The new Ordinary Shares will rank pari passu with the Company’s existing Ordinary Shares.

The total number of Ordinary Shares in issue following Admission will be 42,007,201. Accordingly, the figure of 42,007,201 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

For further information please contact:

Tristel plc

Paul Swinney, Chief Executive Officer
Liz Dixon, Finance Director

Tel: 01638 721 500

Walbrook PR Ltd

Paul McManus
Lianne Cawthorne

Tel: 020 7933 8780 or tristel@walbrookpr.com

Mob: 07980 541 893
Mob: 07854 391 303

finnCap

Geoff Nash (Corporate Finance)
Giles Rolls (Corporate Finance)
Stephen Norcross (Corporate Broking)

Tel: 020 7220 0500